Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Amatuximab: Phase II started

December 7, 2015 8:00 AM UTC

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II ARTEMIS trial to evaluate 5 mg/kg IV amatuximab once weekly with IV pemetrexed and IV cisplatin gi...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article